Introduction
============

The Human Metapneumovirus (hMPV) is a negative single-stranded RNA virus. It belongs to the family Pneumoviridae, which includes the genus Metapneumovirus and Orthopneumovirus, whose main representatives are the Human Metapneumovirus (hMPV) and the Respiratory Syncytial Virus, respectively ([@ref-29]). The hMPV was initially isolated and described in the Netherlands during the year 2001; however, it is presumed that hPMV is responsible for respiratory infections dating back to approximately six decades ([@ref-29]; [@ref-4]; [@ref-22]; [@ref-25]; [@ref-7]). According to the phylogenetic analysis, within the most frequent isolated genotypes, two subgroups of hPMV have been identified: A and B, which include subtypes A1, A2, B1 and B2 ([@ref-7]; [@ref-19]).

Infection due to hMPV mainly affects the pediatric population and can cause diverse pathologies of the upper or lower respiratory tract, which include rhinopharyngitis, laryngitis, croup, pneumonia, bronchiolitis or asthma exacerbations ([@ref-32]; [@ref-6]). Furthermore, it also affects the adult population, predominantly elderly and immunosuppressed patients ([@ref-6]). Although the clinical context most frequently consists of an asymptomatic period that lasts approximately seven days post exposure, followed by a week of symptoms of an upper respiratory tract infection with gradual resolution, the clinical course can progress toward the lower respiratory tract resulting in lung parenchymal involvement and cause further complications ([@ref-5]; [@ref-14]; [@ref-21]; [@ref-34]; [@ref-27]). It is estimated that infections caused by hMPV are accountable for approximately 20,000 hospitalizations per year in children under five years old in the United States ([@ref-12]). However, the available information regarding its epidemiology is limited due to a deficient suspicion and its clinical similarity with other respiratory viruses such as the Influenza virus and the Respiratory Syncytial Virus. It has been described and established in Western countries that the prevalence of the Human Metapneumovirus increases during the late winter months and the beginning of the spring; however, it has also been reported during late spring and summer months in cities such as Hong Kong ([@ref-29]; [@ref-32]; [@ref-24]; [@ref-10]; [@ref-17]). Currently, the limited availability of molecular methods for the precise diagnosis of viral pathologies such as those caused by hMPV leads to poor epidemiological data in Latin American countries such as Peru. The aim of this study is to identify the Human Metapneumovirus responsible for acute respiratory infections in children from September 2009 to September 2010 in Lima, Peru.

Materials and Methods
=====================

Patients
--------

We performed a prospective study between September 2009 and September 2010 in a high complexity national hospital in Lima, Peru. The time frame corresponds to the pandemic of influenza A H1N1. In this study we included all the patients with clinical diagnosis of acute respiratory infections (ARI). We use the operative definition of ARI, according to the sanitary directives of the Ministry of Health of Peru, as any infection that involves one or more parts of the respiratory system, with a duration of less than 14 days and with the presence of one or more clinical signs: cough, rhinorrhea, nasal obstruction, odynophagia, dysphonia, otalgia, noisy breathing, respiratory distress, which may or may not be accompanied by fever. The epidemiological and clinical data were: age, clinical symptoms (fever: defined as temperature higher than 38 °C, rhinorrhea, cough, respiratory difficulty, sore throat, wheezing, discomfort, pharyngeal congestion, expectoration, vomiting, diarrhea, others.).

Ethics statement
----------------

Samples were collected following a written informed consent signed by all the parents or respective caregiver because the patients were under 18 years of age. This study has been approved by two independent Ethics Committees from *Hospital Nacional Cayetano Heredia* (Ethical Application N° 021-09) and *Instituto de Investigación Nutricional* (Ethical Application N° 279-2009 / CEI-IIN) in Lima, Peru.

Samples
-------

To obtain the samples we used two different swabs. A first swab was inserted into both nostrils parallel to the palate to obtain the nasopharyngeal samples (Mini-Tip Culture Direct; Becton-Dickinson Microbiology System, Franklin Lakes, NJ, USA). The second swab was inserted into the posterior pharyngeal and tonsillar areas (Viral Culturette; Becton-Dickinson Microbiology Systems, Franklin Lakes, NJ, USA). A tube containing viral transport medium (minimal essential medium with 2% fetal bovine serum, amphotericin B 20 µg/ml, neomycin 40 µg/ml,) was used to store both swabs. Two aliquots of each fresh specimen were stored at −20 °C to be later analyzed for hMPV.

RNA extraction
--------------

The viral genetic material was extracted used the High Pure RNA Isolation Kit (Roche Applied Science, Mannheim, Germany) to perform the RNA extraction from 200 µL of the samples, according to the manufacturer's instructions. Viral RNA obtained after the extraction was eluted in 100 µl of nuclease-free water.

Reverse Transcriptase Polymerase chain reaction (RT-PCR) for the analysis of Human Metapneumovirus (hMPV)
---------------------------------------------------------------------------------------------------------

A one-step RT-PCR was performed using Real Time ready RNA Virus Master (Roche Diagnostic, Deutschland-Mannheim, Germany) and 250 nM specific primers for hMPV in a final volume of 20 µL. The primers were described by [@ref-29], amplifying a conserved fragment of 170 nt in the polymerase chain. Five microliters of the extracted RNA was combined with 15 µl of the master mix and the reverse transcription step was performed 45 °C for 45 min and the amplification consisted of an initial incubation at 95 °C for 2 min, followed by 45 cycles of 95 °C for 1 min; 50 °C for 1 min, and 72 °C for 30 s; with a final extension at 72 °C for 10 min.

Amplified products were recovered from the gel, purified (SpinPrep Gel DNA Kit; San Diego, CA) and sent for commercial sequencing (Macrogen, Seoul, South Korea).

Statistic analysis
------------------

The data was registered in a database designed in Access and were exported to an Excel file for further analysis. The tabulated data were shown as percentage frequencies or counts. The graphics were prepared with the OriginPro v8 software, and analyzed with the Minitab v18 software.

Results
=======

A total of 539 samples belonging to patients with a clinical context suggestive of an acute respiratory tract infection were analyzed. Of these samples, 73 were positively identified using RT-PCR for hMPV. This finding establishes a prevalence of 13.54% for hMPV in the population studied. Nonetheless, the probability or risk of associating a clinical course of a symptomatic acute respiratory tract infection to the presence of hMPV was less than 3% as demonstrated by the calculated OR ([Table 1](#table-1){ref-type="table"}). This result suggests that other etiological agents (p.e. RSV, influenza, etc.) have a greater probability to be present in the setting of an acute respiratory tract infection ([@ref-1]; [@ref-8]).
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###### Frequency and prevalence of the hMPV infection.
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  Cases       PCR                                                  
  ----------- ----- ------------------------ --------------------- ---------------------
  Positives   73    13.54 \[10.91--16.69\]   0.16 \[0.11--0.20\]   0.03 \[0.01--0.06\]
  Negatives   466   86.46 \[83.31--89.09\]   6.38 \[5.14--7.92\]   
  Total       539   100.00                                         

This study also found that 63% of the positive cases for hMPV identified through PCR corresponded to children under one year of age, and this percentage increased to around 80% when considering children under two years of age. The same distribution was observed in the total cases for acute respiratory tract infections. Thus, in both cases, the age distribution can be adjusted to exponential models ([Fig. 1A](#fig-1){ref-type="fig"}) and where it can clearly be seen that acute respiratory tract infections are more frequent children under two years of age. Additionally, it can be indicated that the sex of children is not a factor associated with the prevalence of hMPV ([Fig. 1B](#fig-1){ref-type="fig"}).

![Distribution of patients by age (A) and sex (B).](peerj-07-7266-g001){#fig-1}

More than 90% of children diagnosed with an hMPV respiratory tract infection identified positively by PCR were hospitalized. In these patients, the most common signs and symptoms were cough which was present in 84.93% cases (*n* = 62), followed by fever with 75.34% (*n* = 55) and rhinorrhea 71.23% (*n* = 52). In addition, 51 patients (69.86%) presented with dyspnea. This distribution of signs and symptoms was similar for both the population of children with a negative PCR for hMPV, and for all the children clinically diagnosed with an acute respiratory tract infection ([Fig. 2A](#fig-2){ref-type="fig"}). It is important to note that of the total of cases studied (*n* = 539), mortality was observed in three patients who happened to be negative via PCR for hMPV infection.

![Clinical symptoms.\
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[Figure 2B](#fig-2){ref-type="fig"}, shows the correlation analysis of the signs and symptoms identified in the group of positive patients for hMPV identified through PCR and the total of patients with an acute respiratory tract infection. Also, between positive and negative patients for hMPV identified through PCR. Clearly, it is observed that in all these cases there is a high correlation (*r* ∼1). This emphazises that a patient with a respiratory tract infection caused by hMPV, can present a wide range of signs and symptoms which can hardly be discriminated from a clinical diagnosis of an acute respiratory tract infection. Respiratory tract infections caused by hMPV have been described as a seasonal pattern of infectious disease ([@ref-1]; [@ref-8]). [Figure 3](#fig-3){ref-type="fig"} shows the monthly and seasonal distribution of the acute respiratory tract infections cases and those with a positive PCR for hMPV. The cases of hMPV appear in the month of December 2009 (*n* = 10), increased during the month of January 2010 (*n* = 15) and the highest number of positive cases were recorded during the month of March 2010 ( *n* = 21) coinciding with the maximum number of cases diagnosed clinically as an acute respiratory tract infection. Seasonality (in this hemisphere) corresponds to 42 cases during the months of summer, 21 cases were reported in the fall and spring was the season with the least prevalence of cases (*n* = 3) ([Fig. 3](#fig-3){ref-type="fig"}).
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Discussion
==========

After its first identification and description in 2001, the Human Metapneumovirus (hMPV) has been detected in patients with respiratory tract infections in Europe, Asia, Oceania, Africa, South America ([@ref-16]; [@ref-11]). In Peru, between the years 2002 and 2003, genotype B1 was isolated by RT-PCR in mainly patients under five years old ([@ref-15]). Nonetheless, due to the clinical course similarity it shares with other respiratory viruses it presents as an obstacle for healthcare providers at the time of establishing the etiological diagnosis of the disease. Therefore, its incidence, most affected population, most frequent clinical presentation and seasonal distribution are not well determined. In the present study, 73 cases were isolated during the 13 months in which samples from patients with a clinical course similar to an influenza infection were evaluated. Of the sampled analyzed 13.54% were positive via PCR for hMPV infection, which represents a percentage that merits consideration of hMPV infection as a differential diagnosis in patients with the aforementioned clinical picture. The available information on seroprevalence suggests that the majority of patients have been infected before the age of five ([@ref-29]). Various studies report a prevalence between 5% and 15% in the pediatric population with a clinical course similar to influenza ([@ref-32]; [@ref-5]; [@ref-10]; [@ref-13]; [@ref-18]; [@ref-28]; [@ref-9]; [@ref-3]; [@ref-33]). It is also known that the majority of cases correspond to children under one year of age and that early age is associated with greater need for hospitalization ([@ref-12]). The findings in the present study are consistent with the literature reviewed, in which 63.01% of positive cases correspond to children under 1 year and 84.93% of cases belong to children under five years old. In relation to the symptoms presented by our study population, ([@ref-32]; [@ref-12]; [@ref-13]) the most frequent symptom was cough, a finding that coincides with our study, in which this symptom was observed with a frequency of 84.93% in the patients who were positive for hMPV. The second most frequent symptom found in our study was fever (75.34%); however, according to different studies it can present with a prevalence ranging from 52% to 86% depending on the series. On the other hand, dyspnea was identified in 69.86% of the patients, which indicates that the lower respiratory tract is usually compromised. In addition, although the classical theory on viral replication suggests that hMPV infection is limited to the respiratory tract, cases have been reported of viral encephalitis in children with respiratory tract infections by hMPV, in which the virus has been isolated postmortem from the cerebrospinal fluid (CSF) ([@ref-20]; [@ref-26]). Of the total number of samples analyzed, four samples came from patients with a clinical diagnosis of Encephalitis; however, after rigorous analysis, none was positive for hMPV infection. It has been described that Human Metapneumovirus infection can cause exacerbations of obstructive conditions such as Asthma and Chronic Obstructive Pulmonary disease ([@ref-31]; [@ref-30]; [@ref-2]). This is important in the context of respiratory infections caused by viruses such as RSV that cause Bronchiolitis in the pediatric population and it has been associated to the development or susceptibility to suffer from asthma in the future ([@ref-23]). In addition, the possibility of partial cross-immunity between both viruses is evaluated, since monoclonal antibodies are capable of neutralizing RSV and hMPV ([@ref-28]; [@ref-9]). The diagnosis of an infection caused by hMPV can be made through serology, direct immunofluorescence, viral culture and RT-PCR. Currently, molecular diagnosis by RT-PCR, either conventional or real-time, offers the highest sensitivity than the rest of diagnostic methods previously described ([@ref-29]; [@ref-32]; [@ref-5]; [@ref-14]; [@ref-13]). In the present study, all the samples were analyzed via RT-PCR to establish the diagnosis of hMPV infection. The seasonality of the virus was observed in the majority of studies during the spring season in western countries; however, in the present study, 57.53% of cases occurred during the summer months, with the month of March exhibiting the highest number of cases (*n* = 21). This finding could be partly explained because more than 80 ARIs were reported during that month, a higher number than any other period during the study. This finding emphasizes the importance of describing the seasonal behavior of hMPV and respiratory viruses that cause similar respiratory clinical courses, so that doctors can use as a tool to make more targeted diagnoses.

A limitation in this study was that we did not evaluate other viral or bacterial etiological agents that could be responsible for coinfections. The clinical characteristics in the presence of coinfection could differ from those with unique infection by hMPV. Another limitation is that the type of sampling in our study supposes a potential selection bias. However, due to our interest in studying the presence of hMPV in patients with ARI, it was the most feasible and efficient sampling selection approach for the context in which it was performed.

Conclusion
==========

Respiratory tract infections caused by hMPV has an important prevalence in Latin American countries, such as Peru. It mainly affects children under one year old and can cause upper and lower respiratory tract infections. It is important to conduct further studies and to provide sustained epidemiological surveillance that allows the attending physician to have the pertinent information available to suspect an infection by hMPV. Moreover, molecular diagnostic methods such as RT-PCR still require standardization; however, it would be ideal if they were available in reference laboratories from all health care facilities in order to provide a specific etiologic diagnosis with the best sensitivity and specificity available.
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